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Purpose or Objective 
Extracranial stereotactic body radiation therapy (SBRT) 
allows delivering high doses per fraction with high 
accuracy to the prostatic gland in a low number of 
fractions. Dose escalation in normofractionaded radiation 
prostate cancer trials showed an increased toxicity. In 
order to evaluate the feasibility and toxicity of a regimen 
of a single dose hypofractionated prostate stereotactic 
boost a phase II study was undertaken. Self-reported 
quality of life (QOL) measures were also obtained in order 
to better define the possible deleterious effect of 
treatment. 
Material and Methods 
Patients included were diagnosed of prostate cancer with 
T3aN0M0 Gleason score 8 or less (N+risk<25%) and IPSS 0-
12. Hormonal-therapy was prescribed according to risk 
classification. Image Guided RT with Cone Beam CT was 
mandatory. Dose SBRT was delivered at a prescribed 
planning target volume (PTV) 9 Gy after 60 Gy 2 Gy per 
fraction in 30 days, using with RapidArc VMAT, with 6 MV 
FFF photons. Equivalence of dose at 2 Gy per fraction, 
using Linear Quadratic Model is round 87Gy. RTOG-EORTC 
and  CTCAE v4.0 morbidity scores were used to assess 
toxicities. Health-related quality of life questionnaire was 
administered centrally by telephone interview before 
treatment and during follow-up (at 3, 6 and 12 months). 
Study was planned following a Simon’s 2-stage design. Due 
to a low recruitment rate firsts 22 evaluable patients were 
studied. 
Results 
First's 22 patients included were analyzed. Mean age was 
69.6 years old.  Median follow-up was 9 months (2-50) with 
more than 60% having at least 6 months of follow-up. 
According to D’Amico risk classification for trial and 
inclusion criteria all of them were high risk. All patients 
completed the treatment as programmed with good 
tolerance. No toxicity greater than grade 2 was observed. 
EPIC urinary values were 81.26 and 80.49 at 6 and 12 
months respectively.  EPIC hormonal was 63.83 
and  64.09  at 6 and 12 months respectively . EPIC bowel 
values for these points in time were 93.30 and 92.50.  Non 
PSA relapse was seeing during this short follow-up.  Acute 
GI grade 2 toxicities were 9.2%  for a week after 
treatment. At the 1st month GI Grade 2 toxicity showed 
the same percentage. At the 3rd month GI Grade 2 was 
reduced to 4.5%. Acute GU grade 2 toxicity was  31.8 %. 
At the 1st month GU Grade 2 toxicity decrease to 9.1%. One 
patient showed late GU Grade 2 at 6 months. 
Conclusion 
SBRT regime of 9 Gy to the prostate after 
normofracionated 60 Gy for high risk prostate cancer is 
feasible and well tolerated in selected patients. Decline 
in QoL values are seen EPIC hormonal QLQ measures are 
related to prolonged hormonal treatment in high-risk 
patients.  Long-term follow-up is needed for assessment 
